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Abstract 
Purpose: To formulate and evaluate sustained-release indomethacin tablets based on solidified reverse 
micellar solution (SRMS).  
Methods: SRMS consisting of mixtures of phospholipid (Phospholipon® 90H) and triglyceride (Softisan® 
154) were prepared in the ratios of 1:1, 2:1 and 1:2, respectively. SRMS-based tablets containing 75 mg 
of indomethacin each were prepared using a validated plastic mould. The physicochemical properties of 
the tablet formulations were studied. In vitro release study was carried out in simulated intestinal fluid 
(SIF, pH 7.5).   
Results: The results showed that the physicochemical properties of the tablet formulations were 
significantly affected by the composition/ratio of the lipid matrix used (p < 0.05). Tablet hardness ranged 
from 5.00 ± 0.39 to 5.60 ± 0.36 kgf for tablets formulated with SRMS 1:2 and 2:1 (N3 and N2), 
respectively. The tablets exhibited friability of < 1 % (p < 0.05).  Erosion time in SIF ranged from 124.0 ± 
0.5 to 180.0 ± 1.1 min while drug release from the tablets reached a maximum in 8 – 11 h for all the 
batches.  
Conclusion: Indomethacin tablets based on SRMS exhibited good sustained-release properties and 
can be further developed to achieve once daily administration for improved patient adherence to 
therapy. 
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Indomethacin is a non-steroidal anti-inflammatory 
drug (NSAID) with prominent anti-inflammatory, 
analgesic and antipyretic properties similar to 
those of the salicylates. It is a more potent 
inhibitor of cyclooxygenase than aspirin. Oral 
indomethacin has excellent bioavailability; 
however, it has a short half-life of about 2.5 h 
and like other NSAIDs, it causes gastric irritation 
[1]. Owing to the short biological half-life of this 
drug, a sustained action dosage form is generally 
preferred, to reduce frequency of administration, 
enhance patients’ compliance, reduce its gastric 
irritation effect and improve its bioavailability 
profile.  
 
Solidified reverse micellar solution (SRMS) 
consisting of phospholipid and solid lipid such as 
Softisan® 154, a completely hydrogenated palm 
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oil, transforms into a lamellar mesophase after 
melting on contact with water. This 
transformation enables controlled release of 
solubilized drugs. SRMS also offer a high 
solubilization rate of different types of drugs [2].  
Numerous polymer-based materials have been 
widely studied as drug carriers in the field of drug 
delivery [3-5]. The use of synthetic polymer 
matrix materials often goes along with 
detrimental effects on incorporated drug during 
manufacturing of formulations or during the 
degradation of the polymers after application [6]. 
The degradation of polymer might possibly cause 
systemic toxic effects through the impairment of 
reticulo-endothelia system (RES) or after 
phagocytosis of particles by human 
macrophages and granulocytes [7]. Therefore, 
alternative carrier substances have been 
investigated. Among them, lipidic materials have 
gained growing attention [8].  
 
SRMS-based carriers have been investigated 
and successfully employed to achieve controlled 
release of drugs [2,9,10]. Lipid based 
formulations have been shown to enhance the 
bioavailability of drugs administered orally [11–
14]. The proven safety (biocompatibility) of lipid 
based carriers makes them attractive candidates 
for the formulation of pharmaceuticals. Lipid 
formulations generally provide increased drug 
solubilization for water insoluble drugs. Drug 
suspended in lipid matrix has been shown, in 
most cases to have a better absorption than 
conventional solid dosage forms [15]. 
Furthermore, bulk lipids are non adhesive and 
therefore, do not adhere to intestinal walls unlike 
most polymers and so present a good matrix for 
the formulation of non-steroidal anti-inflammatory 
drugs (NSAIDS) with high gastric irritation 
tendency.  
 
This work is aimed at formulating sustained 
release indomethacin tablets based on SRMS for 
once daily administration and to evaluate the in 







The following materials were used as procured 
from their suppliers without further purification: 
hydrochloric acid, sodium hydroxide, monobasic 
potassium phosphate and indomethacin (Merck, 
Germany), Softisan® 154 (Schuppen, Condea 
Chemie GmbH, Germany), Phospholipon® 90H 
(Phospholipid GmbH, Köln, Germany), and 
distilled water (Lion water, Nsukka, Nigeria). 
Plastic mould used was constructed in the 
Faculty of Engineering, University of Nigeria, 
Nsukka. All other reagents and solvents were of 
analytical grade and used as supplied.  
 
Preparation of solidified reverse micellar 
solutions (SRMs)  
 
Mixtures of Phospholipon® 90H and Softisan® 
154 (1:1, 1:2 and 2:1 w/w), were prepared by 
fusion. In each case the lipids were weighed, 
melted together and stirred at a temperature of 
70 oC using a magnetic stirrer, until a 
homogenous, transparent white melt was 
obtained. The homogenous mixture was stirred 
at room temperature until solidification [15–,16]. 
 
Thermal analysis  
 
Melting transitions and changes in heat capacity 
of Phospholipon® 90H, Softisan® 154, 
indomethacin, SRMS 1:1, 2:1 and 1:2, were 
determined using differential scanning 
calorimeter (Netzsch DSC 204 F1, Germany). 
About, 10 mg of each sample was placed in an 
aluminum sample pan, hermetically sealed and 
the thermal behaviour determined in the range 
20 – 500 oC, at a heating rate of 10 K/min under 
nitrogen flux (20 ml/min).  
 
Preparation of indomethacin tablets based on 
SRMS  
 
The plastic mould used for tablet production was 
validated by formulating bland or unloaded 
tablets using the lipid matrices. With reference to 
the average weight of the bland tablets prepared 
with 1:1, 1:2 and 2:1 w/w of the SRMS, the 
amount of indomethacin to be incorporated into 
each tablet was calculated. Each of the SRMS 
was weighed out and placed in a crucible; this 
was melted at 70 oC using a magnetic stirrer/hot 
plate. The required amount of the active 
ingredient that would give 75 mg of indomethacin 
per tablet was transferred into the melted lipid 
matrix in the crucible with stirring until a 
homogenous mix was obtained. The 
homogenous mix was scooped into the wells of 
the mould with a clean stainless steel spoon. It 
was allowed to solidify, scraped and allowed to 
dry at room temperature. The tablets were 
pressed out of the plastic mould and allowed to 
dry properly at room temperature.  
 
Tablet friability test  
 
Twenty tablets were randomly selected from 
each batch of the tablet. The tablets were 
dedusted and weighed. They were placed into 
the drum of the friabilator (Erweka GmbH, 
Germany) and rotated 100 times at 25 rpm for 4 
min. The tablets were removed from the 
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friabilator, dedusted again and reweighed. The 
friability result was expressed as loss of mass 
expressed as a percentage of the initial mass 
[17].  
 
Hardness/crushing strength test 
 
This test was carried out using Monsanto-Stokes 
hardness tester (Manesty, England). Ten tablets 
from each batch were randomly selected. Each 
tablet was placed between the jaws of the 
hardness tester and force was applied by 
adjusting the knob of the tester until the tablet 
integrity failed. The results were recorded in kgf. 
 
 Determination of erosion time of tablets   
 
A method described in the European 
Pharmacopoeia was adapted [18].  The test was 
carried out for each batch of the tablet using a 
beaker containing 500 ml of SIF (pH 7.5) 
maintained at 37 ± 1 oC. A thermometer was 
inserted into the medium to maintain the 
temperature. An inner compartment containing 3 
tablets from each batch was tied with a thermo-
resistant thread unto a resort stand, and 
immersed into the medium. The medium was 
stirred at 100 rpm with a magnetic stirrer bar. 
The erosion time was taken as the time taken for 
the tablet to change in shape and erode 
appreciably. This test was repeated three times 
for each batch and the mean erosion time was 
determined. 
 
Content of active ingredient  
 
Beer’s calibration curve was obtained at a 
concentration range of 0.1 – 1.0 mg% for 
indomethacin in SIF (pH 7.5) at a predetermined 
wavelength of 298 nm. Twenty tablets were 
randomly selected from each batch of the tablets. 
The tablets were weighed together and crushed 
in a mortar with a pestle. An amount equivalent 
to the average weight of the crushed tablet was 
weighed out in an analytical balance and 
dispersed in distilled water. The dispersion was 
heated for 30 min at 70 oC using a magnetic 
stirrer/hot plate, to enhance dispersion. This 
dispersion was allowed to cool, filtered and an 
aliquot of the filtrate was assayed using a 
spectrophotometer (Jenway spectrophotometer, 
Barloworld Scientific Ltd., UK). The absorbance 
was recorded and the concentration of 
indomethacin in each tablet was calculated with 
reference to Beer’s plot.   
 
In vitro release studies  
 
USP Apparatus II [17] was used in this study. 
The dissolution medium consisted of 900 ml of 
freshly prepared SIF (pH 7.5). The temperature 
of the medium was maintained at 37 ± 1 oC. A 
tablet from each batch was placed inside a tightly 
secured basket and the basket was placed in the 
bottom of the beaker. The paddle was rotated at 
100 rpm. At various intervals, 5 ml-sample was 
withdrawn from the dissolution medium, filtered 
with a non adsorbent filter paper (Whatman no.1) 
and analysed for drug content 
spectrophotometrically at 298 nm. An equal 
volume of the withdrawn sample was replaced 
with fresh medium to maintain sink condition. 
The amount of drug released at each time 
interval was determined with reference to the 
standard Beer’s plot for indomethacin. 
 
In vitro release kinetics 
 
The dissolution data for the tablets were 
analysed to determine the in vitro release kinetic 
mechanism using three kinetic models including 
the first order equation, Higuchi square root 
equation and Ritger-Peppas empirical model.  
 
        lnQt = lnQ0 - K1t …………………  (1)                                                              
          Qt = K2t1/2  ……………………….  (2) 
         Mt/M∝ = K3tn ……………………… (3) 
 
 where Qt is the amount of drug released or 
dissolved at time t, Q0 is amount of drug released 
or dissolved at time t = 0, k1, k2 and k3 are First-
order, Higuchi and Ritger-Peppas release rate 
constant, Mt/M∝ is the fraction of the drug 
released at time t, n is the diffusion exponent and 
is an indicator of the mechanism of transport of 




Statistical analysis was carried out using SPSS, 
version 14.0 (SPSS Inc Chicago, IL, USA). All 
data are expressed as mean ± SD, and were 
analysed by one-way ANOVA. Differences 
between means were assessed by two-tailed 
Student’s t-test. P < 0.05 was considered 
statistically significant.  
 
RESULTS   
 
The results of thermal analysis of the materials 
are shown in Table 1. The results, the DSC curve 
of Softisan® 154 showed a narrow endothermic 
peak, with melting peak at temperature 61.4 oC. 
Phospholipon® 90H showed a melting peak at 
temperature of 124 oC. Indomethacin DSC 
curves showed a melting peak at 162.2 oC while 
those of the lipid matrices showed that the 
structuring of Softisan® 154 with P90H produced 
matrices with low enthalpies. 
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Table 1: DSC melting peaks of materials used in 
formulating SRMS-based indomethacin tablets 
 
Material Melting peak 
(oC)* 
Softisan® 154 61.4 
Phospholipon 90H 124.0 
Indomethacin 162.2 
SRMS 1:1 65.5 
SRMS 1:2 62.3 
SRMS 2:1 65.0 
SRMS = solidified reverse micellar solution 
 
The results of tablet friability test, hardness, 
crushing strength and erosion time are presented 
in Table 2. All the batches of indomethacin 
tablets exhibited friability of less than 1 % (p < 
0.05), while all the batches of indomethacin 
tablets exhibited hardness of approximately 5 
kgf. The erosion time of tablets showed that the 
tablet batches prepared with different ratios of 
lipid matrices passed the erosion time test. 
Indomethacin tablets formulated with lipid matrix 
(SRMS) 2:1 (N2 tablets) had the highest erosion 
time of 180.40 ± 1.06 min. 
 
The results of drug content of tablets are 
presented in Table 2, from the results, all the 
tablet batches complied with the BP standard for 
assay of active ingredient. All the tablets were 
within the range of 90 to 110 % of the average 
value. 
 
The release profile of indomethacin tablets 
studied in SIF (pH 7.5) is presented in Fig. 1. The 
results showed that indomethacin tablets 
formulated with the lipid matrix, SRMS 1:1 (N1) 
had the fastest release of the NSAID with 
maximum release at 8 h. This was followed by 
tablets formulated with the lipid matrix, SRMS 1:2 
(N3), which had 100 % drug release at 10 h. 
Tablets formulated with LM 2:1 (N2) had the 
longest release rate with maximum release at 11 
h. This may be due to the high softening and 
erosion time exhibited by this lipid matrix. 
Indomethacin tablets formulated with lipid matrix, 
SRMS 2:1 had maximum release at 11 h, while 
indomethacin pure sample had maximum release 
at 1 h. The results of drug release kinetics and 
mechanisms presented in Table 2 indicated that 
the Higuchi plot of amount of drug release (Q) 
against square root of time was linear (r2 > 0.9) 
for all the batches of indomethacin tablet 
formulations. Also plot of log Q versus log t gave 
n value of ≤ 0.5 as shown in Table 2. The first 
order plots, however, showed low level of 
linearity (0.7 < r2 < 0.9). The Ritger–Peppas 
model for indomethacin tablets showed an n 
value of < 0.5 for all the tablets formulations.  
 
Fig 1: Release profile of three batches of 
indomethacin sustained release tablets; ♦ = N1 (1:1), □ 
= N2 (2:1), Δ = N3 (1:2), and ● = R2 (indomethacin pure 
sample) 
 
       Table 2: Some properties of SRMS based indomethacin sustained release tablets  
 
Batch Hardness 




(min, ±SD, n=10) 
Drug content 
(mg, ±CV, n=20) 
N1  5.10 ± 0.24 0.07 134.00 ± 2.80 75.27 ± 0.39 
N2  5.60 ± 0.36 0.06 180.00 ± 1.10 75.12 ± 1.10 
N3  5.00 ± 0.39 0.09 124.00 ± 0.50 75.20± 0.75 
CV = coefficient of variation; SD = standard deviation; LM = lipid matrix; NI - N3 = indomethacin tablets prepared with 
LM 1:1, 2:1 and 1:2, respectively. 









(n)   
N1 0.9864 0.4750 0.7380 0.4780 
N2 0.9877 0.5120 0.8212 0.5180 
N3 0.9406 0.2530 0.8037 0.2480 
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The DSC measurements were carried out in 
order to determine the melting points of 
indomethacin, Softisan®, Phospholipon® 90H, 
SRMS 1:1, 2:1 and 1:2. The narrow melting peak 
of Softisan®154 indicates the level of purity of the 
lipid. The thermograms of Phospholipon® 90H 
show that the lipid consists entirely of stable form 
because of the sharp melting peak seen. The 
sharp peak of indomethacin sample indicated the 
presence of pure crystalline indomethacin and 
the value obtained is comparable to the melting 
temperature recorded for indomethacin in the BP 
[17]. Reduction in enthalpy seen in the DSC 
results of the lipid matrices generally suggest 
less crystallinity of lipid matrices [9]. SRMS 1:1, 
2:1 and 1:2 generated imperfect matrices (due to 
distortion of crystal arrangement of individual 
lipids after melting and solidification), which may 
have created numerous spaces for drug 
localization [9].  
 
Indomethacin tablets based on SRMS were 
smooth and spherical with no form of 
depressions or cracks seen in any of the 
batches. The nature of drug contributed to the 
smooth and uniform surface seen in the tablets. 
Indomethacin solubilized in the lipid matrix and 
gave light yellow tablets. The results of tablets 
friability showed that the tablets can withstand 
handling, packaging and transportation without 
affecting the integrity of the products. The results 
of crushing strength showed that the mechanical 
properties of the tablet will not be compromised 
during long term storage. Erosion time is 
important because the tablet should erode 
appreciably in order to enhance drug release and 
make the drug available for absorption. 
Sustained release preparation and enteric coated 
tablets are expected to disintegrate or erode 
appreciably in SIF within 2 h [20]. However, 
batch N2 had erosion time of up to 180 min; this 
may be due to the lipophilicity of the drug in the 
lipid matrix and formation of more compact 
matrix seen in lipid matrix, SRMS 2:1.  
 
The results of drug content showed that the drug 
was not lost either by physical or chemical 
means uniformity of content. The release profiles 
of the drug show that the rate of indomethacin 
release from tablet formulations were not 
comparable to the pure sample of indomethacin 
used as the reference sample. The ratio of 
phospholipid in the lipid matrix affected the rate 
of drug release. Increase in phospholipid ratio 
prolonged the rate of drug release and this may 
be due to the increase in hardness, softening 
and erosion time seen when the ratio of 
phospholipid was increased above Softisan® 
ratio, i.e., batch N2. All the batches of 
indomethacin exhibited good release properties 
and are recommended for the formulation of 
sustained release preparations for once daily 
administration.  
 
Higuchi release data show an n value of < 0.51 
which confirms that diffusion-controlled process 
was predominant mechanism of drug release 
[21]. Ritger–Peppas model for indomethacin 
tablets indicate that the tablet formulations 
exhibited Fickian diffusion release mechanism 




SRMS can be used to formulate sustained 
release indomethacin for once daily 
administration to reduce the frequency of 
administration of this drug, increase its 
bioavailability, enhance patients’ compliance and 
reduce some side effect due to high dosing, 
amongst others. However, further research into 
this field of research is recommended for scale-
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